Immune Checkpoint Inhibitors | Real World Brand Tracker | US | 2019
Immune checkpoint inhibitors continue to revolutionize current oncology treatment. Driven by Decision Resources Group’s in-house oncology experts and robust real-world data capabilities, the Real World Brand Tracker captures U.S. claims data to uncover shifting market dynamics and the impact of events on the immune checkpoint inhibitor space, in order to help refine your oncology brand strategies. We cover every approved immune checkpoint inhibitor for every approved oncology indication and monitor the trends in use and reimbursement dynamics over time.
Questions answered:
- How is the uptake for individual immune checkpoint inhibitor brands changing over time?
- Which brand is winning, and how does that vary by indication?
- How does the dynamic regulatory environment for immune checkpoint inhibitors in the U.S. affect prescribing patterns of currently approved immune checkpoint inhibitors by indication?
- What is the average claim charge for each immune checkpoint inhibitor brand and how much if the claim is paid?
- In which type of facilities are patients receiving immune checkpoint inhibitors?
Related Market Assessment Reports
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
